



NEWS RELEASE

FOR IMMEDIATE RELEASE

SeptRx® completes enrollment for its “InterSEPT” CE mark trial, partners with CoRRect Medical GmbH for European distribution of its SeptRx® Intrapocket PFO Occluder (IPO)

SeptRx® IPO is designed to close “hole in the heart” defects and lower the risk of stroke, the second-leading cause of death worldwide

FREMONT, Calif., April 23, 2012 — [SeptRx®](#), an emerging medical device company that has developed the **SeptRx® Intrapocket PFO Occluder (IPO)** — a platform for the percutaneous transcatheter closure of a heart defect known as *patent foramen ovale* (PFO) — reported today that it has completed enrollment for its “InterSEPT” (In-tunnel SeptRx European PFO Trial) clinical trial in Europe, and has entered into a partnership with **CoRRect Medical GmbH** for commercial distribution in Germany and Switzerland of the SeptRx® IPO.

The Company intends that InterSEPT data will be used to apply for CE marking of the SeptRx® IPO device in the second half of 2012, at which time commercial distribution will begin. **The SeptRx® IPO has previously completed a successful 11-patient first-in-human (F-I-H) clinical trial, which demonstrated 100% closure and 100% safety out to 3 years.**

“CoRRect Medical is committed to bringing innovative technologies to market,” said **Michael Braun**, General Manager of CoRRect Medical. “The SeptRx IPO device is an elegant, next-generation medical device. We are extremely proud to be the first distributor to represent SeptRx’s breakthrough device in Europe.”

“We look forward to completing the InterSEPT trial in a successful and timely fashion. We are on schedule for applying for CE mark in the second half of this year,” said **Scott Russell**, SeptRx’s CEO. “Engaging an outstanding medical distribution partner such as CoRRect underscores our resolve to gain marketing approval of the SeptRx IPO device in Europe in the near term.”

PFO is a tunnel-like defect connecting the right atrium with the left atrium. A remnant of fetal circulation, it usually seals itself within a few months after birth. Unfortunately, in about 25% of the population the *PFO* does not fully close and may allow blood (and emboli) to pass directly between the right and left atria. The presence of a *PFO* has been identified as a contributing factor in cryptogenic stroke, chronic migraine, decompression sickness, and obstructive sleep apnea. A *PFO* contributes to these conditions by providing a pathway for emboli (blood clots, air bubbles) in the venous system to reach the arterial system by passing directly from the right atrium to the left.

[CoRRect Medical GmbH](#) specializes in the commercialization and distribution of high-quality and innovative medical device products for cardiology, vascular surgery and cardiac surgery using minimally invasive procedures.

SeptRx, Inc. is an emerging medical device company that has developed the SeptRx® Intrapocket PFO Occluder (IPO), a platform for the percutaneous transcatheter closure of a heart defect known as patent foramen ovale (PFO).

NOTICE: The SeptRx® IPO is not approved for sale in any regulatory jurisdiction. Further, it is not yet available for investigational use or commercial sale in the U.S.

#####